STAT+: Expert warns of battleground over global access to newer GLP-1 drugs for obesity

STAT+: Expert warns of battleground over global access to newer GLP-1 drugs for obesity

Over the past few months, lower-cost generic versions of the blockbuster GLP-1 drug semaglutide, which is sold as Wegovy by Novo Nordisk for combating obesity, started to become available in some countries and will soon arrive in still others. Meanwhile, the pharmaceutical industry is racing to develop newer GLP-1 medicines that, to varying degrees, are forecast to be more effective, cause fewer side effects, and are easier to administer. On one hand, these developments suggest more people than ever before may find needed help for losing weight. But there is another possibility: Obesity medications may become the next big battleground over access to medicines in lower-income countries, according to Ken Shadlen, a London School of Economics professor who studies the politics of pharmaceutical and health regulation. We spoke with him about the looming challenges that may soon confront drugmakers, governments, and patients. This is an edited version of our conversation. You’re making a provocative point, although newer GLP-1 drugs that are better or easier to use or safer are not yet here. Why is it important to raise the issue now? STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? Log in View All Plans To read the rest of this story subscribe to STAT+. Subscribe

Original Source

Read the full article at Statnews →

KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.